

**15 August 2017**

## **Osprey Medical – Notice to Nominees**

**Minnesota, United States and Melbourne, Australia – Osprey Medical Inc. (ASX:OSP) (Osprey or Company)** confirms that on 14 August 2017 it despatched the attached notice to holders of CHES Depository Interests (**CDIs**) who it believes may be holding CDIs as a nominee in relation to the fully underwritten, non-renounceable entitlement offer announced to the market on 4 August 2017.

### **About Osprey**

Osprey Medical is focused on protecting patients from the harmful effects of X-ray dye (contrast) used during commonly performed angiographic imaging procedures. The Company's core technologies originated from research conducted by Dr David Kaye at Melbourne's Baker IDI Heart and Diabetes Institute. Its proprietary dye reduction and monitoring technologies are designed to help physicians minimize dye usage. The Company's DyeVert™ System is a next-generation product that reduces contrast while maintaining image quality in a self-adjusting easy-to-use design. Osprey Medical's Board and Management are comprised of experienced and successful personnel with established track records covering medical device development, regulatory approvals, sales and marketing, and mergers-acquisitions. Osprey Medical's advisory board comprises world-recognised experts in heart and kidney diseases.

### **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on management's beliefs, assumptions and expectations and on information currently available to management.

All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements, including without limitation our expectations with respect to our ability to commercialize our products including our estimates of potential revenues, costs, profitability and financial performance; our ability to develop and commercialize new products including our ability to obtain reimbursement for our products; our expectations with respect to our clinical trials, including enrolment in or completion of our clinical trials and our associated regulatory submissions and approvals; our expectations with respect to the integrity or capabilities of our intellectual property position.

Management believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Osprey does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Osprey may not actually achieve the plans, projections or expectations disclosed in forward-looking statements, and actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

US OFFICE & HEADQUARTERS: Suite 250 | 5600 Rowland Road | Minnetonka MN 55343 | Tel: +1 952.955.8230 | Fax: +1 952.955.8171 |

AUSTRALIAN OFFICE: Level 13, 41 Exhibition Street | Melbourne VIC 3000 | Tel: +61 410 442 393 | Fax: +61 3 9663 6609 |

AUSTRALIAN POSTAL ADDRESS: PO BOX 18355 | Collins Street East | Melbourne VIC 8003

Osprey Medical Inc. (ARBN 152 854 923) is a foreign company incorporated in Delaware, USA.

[www.ospreymed.com](http://www.ospreymed.com)

### Foreign Ownership Restriction

Osprey's CHES Depository Interests (CDIs) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (Securities Act) for offers or sales which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. The holders of Osprey's CDIs are unable to sell the CDIs into the US or to a US person unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. Hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

| Media  | Investors  | Company   |
|--|--|---|
| Gavin Lower<br>Buchan Consulting<br>T: (613) 8866 1215<br><a href="mailto:glower@buchanwe.com.au">glower@buchanwe.com.au</a> | Rebecca Wilson<br>Buchan Consulting<br>M: (61) 417 382 391<br><a href="mailto:rwilson@buchanwe.com.au">rwilson@buchanwe.com.au</a> | Doug Schoenberg<br>VP of Marketing<br>T: (952) 955 8230<br><a href="mailto:dschoenberg@ospreymed.com">dschoenberg@ospreymed.com</a> |

US OFFICE & HEADQUARTERS: Suite 250 | 5600 Rowland Road | Minnetonka MN 55343 | Tel: +1 952.955.8230 | Fax: +1 952.955.8171 |

AUSTRALIAN OFFICE: Level 13, 41 Exhibition Street | Melbourne VIC 3000 | Tel: +61 410 442 393 | Fax: +61 3 9663 6609 |

AUSTRALIAN POSTAL ADDRESS: PO BOX 18355 | Collins Street East | Melbourne VIC 8003

Osprey Medical Inc. (ARBN 152 854 923) is a foreign company incorporated in Delaware, USA,  
whose stockholders have limited liability.

[www.ospreymed.com](http://www.ospreymed.com)



14 August 2017

Dear holder of CHES Depositary Interests

**Entitlement Offer – notice to nominees**

On 4 August 2017, the Board of Osprey Medical Inc. ARBN 152 854 923 (ASX:OSP) (**Osprey**) announced a pro rata, non-renounceable entitlement offer of approximately 25,785,924 new CHES Depositary Interests (**New CDIs**) (representing approximately 12,892,962 new fully paid shares of common stock in Osprey) at an issue price of \$0.40 per New CDI to raise approximately \$10.3 million before costs and expenses (**Entitlement Offer**).

The Entitlement Offer is made to all securityholders who are registered as holders of CDIs at 7.00pm (Melbourne time) on Wednesday 9 August 2017, with a registered address in Australia, New Zealand, Hong Kong or Singapore (**Eligible Holders**). CDI holders with a registered address outside Australia, New Zealand, Hong Kong or Singapore are considered ineligible securityholders and cannot participate in the Entitlement Offer.

The Entitlement Offer Booklet and Entitlement and Acceptance Form is being sent separately.

Osprey is sending you this notice as it believes you may be holding CDIs in Osprey as a nominee.

Osprey wishes to advise you that, due to certain legal restrictions, you must not send copies of the Entitlement Offer Booklet or any other material relating to the Entitlement Offer to, or submit an Entitlement and Acceptance Form or otherwise purchase New CDIs on behalf of, any of your clients (or any other person) who is in the United States or who is not an Eligible Holder and on whose behalf you are the registered owner of the CDIs.

Failure to comply with these restrictions may result in violations of applicable securities laws.

Yours faithfully

A handwritten signature in black ink, appearing to read "B. Case", followed by a vertical line.

**Brendan Case**  
Company Secretary